Available Technologies
# of Displayed Technologies: 2 / 2
Applied Category Filter (Click To Remove): Respiratory Syncytial Virus (RSV)
Categories
.png)
Increasing the Yield of Respiratory Syncytial Virus Live Attenuated Vaccines
TS-000214 — Preventing RSV attachment protein cleavage in vaccine producing cells to increase yield.
A widespread economic problem of RSV vaccine candidates is their inefficient production. RSV vaccine candidates are produced in Vero, a cell line isolated from African green monkey kidney. Infectious disease experts at Nationwide Children’s Hospital have discovered RSV grown in Vero cells has …
- College:
- Inventors: Peeples, Mark; Corry, Jacqueline; Kwilas, Steve
- Licensing Officer: Zalucha, Ellen
.png)
Enhanced Immunogenicity of a Modified Respiratory Syncytial Virus Vaccine with Mutations in One or Both Non-Structural Proteins
TS-000132 — Mutation of the RSV NS1/2 proteins to attenuate the virus and boost immunogenicity
Respiratory syncytial virus (RSV) is the leading cause of upper and lower respiratory tract infections in infants and young children, and the most common cause of bronchiolitis and pneumonia in children younger than 1-year of age. A vaccine does not exist in part because RSV non-structural protein g…
- College:
- Inventors: Peeples, Mark; Flano, Emilio; Mejias, Asuncion; Ramilo, Octavio; Teng, Michael Nan-hao (Mark)
- Licensing Officer: Zalucha, Ellen
